The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes in this quarterly report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K and under the heading “Cautionary Statement Under the Private Securities Litigation Reform Act” discussed elsewhere in this quarterly report. This discussion includes certain non-GAAP financial measures that have been defined and reconciled to the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) under the headings “Non-GAAP Disclosures” and “Free Cash Flow.” This discussion also includes Operating working capital, which has been defined under the heading “Liquidity and Capital Resources.” The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated. Overview IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business, as well as by the relationship of the U.S. Dollar to other currencies. Levels of capacity utilization and capital spending in certain markets and overall industrial activity are important factors that influence the demand for IDEX’s products. Highlights (All comparisons are against the same period in 2025 unless otherwise noted) Three Months Ended June 30, 2026 •Reported Net sales of $920.6 million increased 6% overall and increased 5% organically* •Reported diluted earnings per common share (“EPS”) attributable to IDEX of $1.93 increased 11% •Adjusted diluted EPS attributable to IDEX* of $2.32 increased 12% •Returned capital to shareholders in the form of $77.1 million of share repurchases and $53.9 million of dividends *These are non-GAAP measures. See the definitions of these non-GAAP measures and reconciliations to their most directly comparable U.S. GAAP financial measures under the heading “Non-GAAP Disclosures.” During the second quarter of 2026, the Company delivered strong results. Higher than anticipated volumes continued in targeted advantaged markets, including data centers, semiconductor and space and defense, primarily within the Health & Science Technologies (“HST”) segment. The net impact of IEEPA tariff refunds (defined and described below) more than offset a challenging prior year price/cost comparison and contributed an $0.08 benefit to EPS. Recent Developments On February 20, 2026, the U. S. Supreme Court issued a decision invalidating the broad-based tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”). The Company collected substantially all of the anticipated refunds of previously paid IEEPA tariffs during the second quarter of 2026, resulting in a $22.0 million reduction of Cost of sales as well as a $14.7 million reduction of Net sales from expected customer rebates associated with the refunds. In response to the U.S. Supreme Court ruling, the administration implemented new tariffs under alternative statutory authority and may continue implementing other additional tariffs. The tariffs enacted in 2025 and in the first quarter of 2026 did not have a material impact on the Company’s business or financial statements in the periods presented. 26 Table of Contents Results of Operations The following is a discussion and analysis of the Company’s results of operations for the three and six months ended June 30, 2026 compared with the three and six months ended June 30, 2025. Three Months Ended June 30, Change Six Months Ended June 30, Change (In millions, except per share amounts) 2026 2025 $ % / bps 2026 2025 $ % / bps Domestic sales $ 467.1 $ 435.8 $ 31.3 7 % $ 924.2 $ 855.2 $ 69.0 8 % International sales 453.5 429.6 23.9 6 % 883.3 824.5 58.8 7 % Net sales 920.6 865.4 55.2 6 % 1,807.5 1,679.7 127.8 8 % Cost of sales 493.8 473.2 20.6 4 % 982.6 918.6 64.0 7 % Gross profit 426.8 392.2 34.6 9 % 824.9 761.1 63.8 8 % Gross margin 46.3 % 45.3 % n/a 100 bps 45.6 % 45.3 % n/a 30 bps Selling, general and administrative expenses 224.1 203.6 20.5 10 % 442.4 413.0 29.4 7 % Restructuring expenses and asset impairments 2.8 0.7 2.1 300 % 10.2 18.2 (8.0) (44 %) Operating income 199.9 187.9 12.0 6 % 372.3 329.9 42.4 13 % Other (income) expense – net (1.3) 2.4 (3.7) (154 %) (1.9) 3.8 (5.7) (150 %) Interest expense – net 15.1 15.6 (0.5) (3 %) 31.1 31.7 (0.6) (2 %) Income before income taxes 186.1 169.9 16.2 10 % 343.1 294.4 48.7 17 % Provision for income taxes 42.7 38.8 3.9 10 % 79.8 67.9 11.9 18 % Effective tax rate 23.0 % 22.9 % n/a 10 bps 23.3 % 23.1 % n/a 20 bps Net income attributable to IDEX $ 143.4 $ 131.6 $ 11.8 9 % $ 263.4 $ 227.1 $ 36.3 16 % Diluted earnings per common share attributable to IDEX $ 1.93 $ 1.74 $ 0.19 11 % $ 3.54 $ 3.00 $ 0.54 18 % Net Sales Net sales for the three and six months ended June 30, 2026 increased as compared to the same prior year periods primarily as a result of increased organic sales, as well as favorable impacts from foreign currency and contributions from acquisitions. Organic sales for the same periods both increased 5%, primarily driven by higher volumes in the HST segment, which were partially offset by lower volumes in the Company’s Fire & Safety/Diversified Products (“FSDP”) segment, while volumes in the Company’s Fluid & Metering Technologies (“FMT”) segment were reasonably flat in both periods. The increase in both periods also reflects positive price. Net sales for the three and six months ended June 30, 2026 included a $14.7 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds. Gross Profit and Gross Margin Gross profit and Gross margin for the three and six months ended June 30, 2026 were positively impacted by volume leverage, net operational productivity improvements and positive price/cost. Positive price/cost was driven by the net benefit of IEEPA tariff refunds of $7.3 million, which benefited Gross margin for the three and six months ended June 30, 2026 by 150 basis points and 70 basis points, respectively, and more than offset a challenging prior year price/cost comparison. These improvements were partially offset by unfavorable mix. Gross profit for the three and six months ended June 30, 2026 also reflected favorable impacts from foreign currency. Selling, General and Administrative Expenses Selling, general and administrative expenses increased for the three and six months ended June 30, 2026, reflecting a $2.8 million and $5.5 million increase from acquisitions, including amortization, respectively, as well as higher employee-related costs, including variable compensation, and increased professional services spending, partially offset by proceeds received related to legal settlements, as compared to the same prior year periods. 27 Table of Contents Restructuring Expenses and Asset Impairments Restructuring expenses and asset impairments for the three months ended June 30, 2026 primarily relate to severance costs that were incurred as a result of employee reductions. The six months ended June 30, 2026 also include asset impairments of $4.8 million related to intangible assets and property, plant and equipment within the Company’s FMT segment. Restructuring expenses and asset impairments for the three and six months ended June 30, 2025 primarily relate to severance costs that were incurred in conjunction with organizational changes. Other (Income) Expense – Net Other (income) expense – net during the three and six months ended June 30, 2026 reflects the impact of foreign currency transaction gains, while the three and six months ended June 30, 2025 reflects the impact of foreign currency transaction losses. Interest Expense – Net Interest expense – net for the three and six months ended June 30, 2026 decreased due to interest income of $0.6 million associated with IEEPA tariff refunds received. Income Taxes The effective tax rate was 23.0% and 23.3% for the three and six months ended June 30, 2026, respectively, reasonably consistent with 22.9% and 23.1% during the respective same periods in 2025. For additional information, refer to Note 15, “Income Taxes”, in the Notes to Condensed Consolidated Financial Statements. 28 Table of Contents Results of Reportable Business Segments The Company has three reportable segments: Health & Science Technologies (“HST”), Fluid & Metering Technologies (“FMT”) and Fire & Safety/Diversified Products (“FSDP”). For a detailed description of the operations within each segment, refer to Note 13, “Business Segments and Geographic Information,” in the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Management’s measurements of segment performance are Net sales, Adjusted EBITDA and Adjusted EBITDA margin. See the section below titled “Non-GAAP Disclosures” for definitions of Adjusted EBITDA and Adjusted EBITDA margin. The table below illustrates the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the three and six months ended June 30, 2026. Three Months Ended June 30, 2026 Six Months Ended June 30, 2026 HST FMT FSDP Total HST FMT FSDP Total Net sales as a percent of total 45 % 34 % 21 % 100 % 45 % 34 % 21 % 100 % Adjusted EBITDA(1) 42 % 39 % 19 % 100 % 41 % 39 % 20 % 100 % (1) Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $26.2 million and $56.3 million for the three and six months ended June 30, 2026, respectively. Health & Science Technologies Segment Three Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div(1) Foreign Currency Total Domestic sales $ 186.0 $ 166.3 12% International sales 229.0 199.0 15% Net sales $ 415.0 $ 365.3 14% 12% 2% —% 14% Adjusted EBITDA 119.3 95.0 26% 25% —% 1% 26% Adjusted EBITDA margin 28.7 % 26.0 % 270 bps 310 bps (40) bps — bps 270 bps Six Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div(1) Foreign Currency Total Domestic sales $ 371.7 $ 321.4 16% International sales 441.7 385.4 15% Net sales $ 813.4 $ 706.8 15% 11% 2% 2% 15% Adjusted EBITDA 225.3 182.4 24% 22% —% 2% 24% Adjusted EBITDA margin 27.7 % 25.8 % 190 bps 240 bps (50) bps — bps 190 bps (1) Acquisitions include Micro-LAM, Inc. acquired in July 2025. •Organic sales for the three and six months ended June 30, 2026 reflect higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense and positive price. Net sales for both the three and six months ended June 30, 2026 included a $9.3 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth by 2% for both periods. •Adjusted EBITDA margin for the three and six months ended June 30, 2026 increased primarily due to volume leverage. Higher variable compensation and the impact of acquisitions more than offset positive price/cost. Positive price/cost was driven by the net impact from IEEPA tariff refunds, which benefited Adjusted EBITDA margin for the three and six months ended June 30, 2026 by 90 basis points and 50 basis points, respectively. While mix had a 29 Table of Contents favorable impact on Adjusted EBITDA margin for the three months ended June 30, 2026, mix negatively impacted Adjusted EBITDA margin for the six months ended June 30, 2026. Fluid & Metering Technologies Segment Three Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div(1) Foreign Currency Total Domestic sales $ 183.7 $ 175.7 5% International sales 133.4 135.2 (1%) Net sales $ 317.1 $ 310.9 2% 1% —% 1% 2% Adjusted EBITDA 110.3 108.7 1% 1% —% —% 1% Adjusted EBITDA margin 34.8 % 35.0 % (20) bps (20) bps — bps — bps (20) bps Six Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div Foreign Currency Total Domestic sales $ 359.4 $ 344.5 4% International sales 259.2 256.9 1% Net sales $ 618.6 $ 601.4 3% 2% —% 1% 3% Adjusted EBITDA 209.0 204.0 2% 1% —% 1% 2% Adjusted EBITDA margin 33.8 % 33.9 % (10) bps (10) bps — bps — bps (10) bps •Organic sales for the three and six months ended June 30, 2026 reflect positive price. Volumes in both periods were reasonably flat with higher volumes in the Company’s businesses serving municipal water, semiconductor and mining markets offset by lower volumes in the Company’s businesses serving the energy, agriculture and chemical markets. Net sales for both for the three and six months ended June 30, 2026 included a $3.2 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth by 2% for the three months ended June 30, 2026, but only had a minimal impact for the six months ended June 30, 2026. •Adjusted EBITDA margin for the three and six months ended June 30, 2026 decreased due to unfavorable mix and higher variable compensation, the impacts of which were mostly mitigated by net productivity improvements and positive price/cost. Positive price/cost was driven by the net impact from IEEPA tariff refunds, which benefited Adjusted EBITDA margin for the three and six months ended June 30, 2026 by 180 basis points and 90 basis points, respectively, more than offsetting a challenging prior year price/cost comparison. 30 Table of Contents Fire & Safety/Diversified Products Segment Three Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div Foreign Currency Total Domestic sales $ 97.4 $ 93.8 4% International sales 92.5 97.7 (5%) Net sales $ 189.9 $ 191.5 (1%) (1%) —% —% (1%) Adjusted EBITDA 54.9 56.4 (3%) (3%) —% —% (3%) Adjusted EBITDA margin 28.9 % 29.4 % (50) bps (40) bps — bps (10) bps (50) bps Six Months Ended June 30, Components of Change (In millions) 2026 2025 Change Organic Acq/Div Foreign Currency Total Domestic sales $ 193.1 $ 189.3 2% International sales 185.1 186.5 (1%) Net sales $ 378.2 $ 375.8 1% (1%) —% 2% 1% Adjusted EBITDA 110.7 110.6 —% (1%) —% 1% —% Adjusted EBITDA margin 29.3 % 29.4 % (10) bps (10) bps — bps — bps (10) bps •Organic sales for the three and six months ended June 30, 2026 reflect higher volumes in the Company’s BAND-IT business and positive price, which was more than offset by lower volumes in other FSDP businesses, resulting from the Company’s Fire & Safety businesses, driven by lower European rescue demand during the three months ended June 30, 2026 and the Company’s Dispensing businesses during six months ended June 30, 2026. Net sales also included a $2.2 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth for both the three and six months ended June 30, 2026 by 1%. •Adjusted EBITDA margin decreased for the three and six months ended June 30, 2026 primarily due to unfavorable mix and volume deleverage, partially offset by net productivity improvements and positive price/cost. Positive price/cost was driven by the net impact from IEEPA tariff refunds, which benefited Adjusted EBITDA margin for the three and six months ended June 30, 2026 by 120 basis points and 60 basis points, respectively, more than offsetting a challenging prior year price/cost comparison. 31 Table of Contents Liquidity and Capital Resources Liquidity Based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its cash requirements, including funding of working capital, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. The Company believes that additional borrowings through various financing alternatives remain available, if required. Select key liquidity metrics at June 30, 2026 are as follows: (In millions) June 30, 2026 Working capital $ 1,191.7 Current ratio 3 to 1 Cash and cash equivalents $ 621.3 Cash held outside of the United States 514.0 Revolving Facility capacity $ 800.0 Borrowings 266.3 Letters of credit 4.1 Revolving Facility availability $ 529.6 Operating Working Capital Operating working capital, calculated as Receivables – net plus Inventories – net minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details Operating working capital as of June 30, 2026 and December 31, 2025: (In millions) June 30, 2026 December 31, 2025 Change Organic Change Receivables – net $ 547.8 $ 521.7 $ 26.1 $ 30.8 Inventories – net 520.3 479.4 40.9 45.8 Less: Trade accounts payable 233.7 224.7 9.0 11.1 Operating working capital $ 834.4 $ 776.4 $ 58.0 $ 65.5 Acquisitions and foreign currency translation decreased Operating working capital by $7.5 million during the six months ended June 30, 2026. Apart from these items, the primary drivers of the change in Operating working capital were higher sales volumes and positive price leading to higher receivables and higher inventories, which increased to support planned production. The increase in Operating working capital was partly offset by expected customer rebates associated with IEEPA tariff refunds. 32 Table of Contents Cash Flow Summary The following table is derived from the Condensed Consolidated Statements of Cash Flows: Six Months Ended June 30, (In millions) 2026 2025 Change Net cash flows provided by (used in): Operating activities $ 303.7 $ 267.4 $ 36.3 Investing activities (42.7) (24.5) (18.2) Financing activities (208.1) (349.2) 141.1 Operating Activities Cash provided by operating activities increased $36.3 million in the six months ended June 30, 2026 as compared to the prior year period. Improved operational results and cash received for IEEPA tariff refunds of $21.1 million was partially offset by higher operating working capital discussed above. Investing Activities Cash used in investing activities increased $18.2 million in the six months ended June 30, 2026 as compared to the prior year period reflecting a $11.6 million increase in capital expenditures and the absence of $4.2 million of funds received in connection with the finalization of the Mott purchase price in the prior year period. Financing Activities Cash used in financing activities decreased $141.1 million in the six months ended June 30, 2026 as compared to the prior year period. The six months ended June 30, 2026 included $84.4 million of higher net draws under the Revolving Facility and $10.8 million of higher proceeds from stock option exercises, net of shares withheld for taxes, partially offset by $53.4 million of higher share repurchases. The six months ended June 30, 2025 also included a $100.0 million payment on long-term borrowings that did not reoccur in the current year period. Free Cash Flow The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures. The following table reconciles cash flows provided by operating activities to free cash flow: Six Months Ended June 30, (In millions) 2026 2025 Cash flows provided by operating activities $ 303.7 $ 267.4 Less: capital expenditures 40.7 29.1 Free cash flow $ 263.0 $ 238.3 Cash Requirements Subsequent Share Repurchases Subsequent to June 30, 2026, the Company repurchased 0.1 million shares at a cost of $21.7 million. 33 Table of Contents Capital Expenditures Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $40.7 million and $29.1 million in the first six months of 2026 and 2025, respectively. Share Repurchases During the six months ended June 30, 2026, the Company paid $153.4 million for share repurchases, comprised of $148.9 million for shares repurchased and settled during the period, $2.2 million for shares repurchased in December 2025 that settled in January 2026 and $2.3 million of excise taxes for shares repurchased in 2025. During the six months ended June 30, 2025, the Company paid $100.0 million for shares repurchased and settled during the period. As of June 30, 2026, the amount of share repurchase authorization remaining was $774.7 million, excluding fees, commissions, excise taxes and other expenses related to such common stock repurchases. For additional information regarding the Company’s share repurchase program, refer to Note 11, “Share Repurchases,” in the Notes to Condensed Consolidated Financial Statements. Dividends Total dividend payments to common shareholders were $106.7 million during the six months ended June 30, 2026 compared with $105.9 million during the six months ended June 30, 2025. Covenants At June 30, 2026, the Company was in compliance with the covenants contained in the credit agreement associated with the Revolving Facility as well as other long-term debt agreements. The key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the 5.13% Senior Notes, are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1. At June 30, 2026, the Company’s interest coverage ratio was 14.17 to 1 for covenant calculation purposes and the leverage ratio was 1.87 to 1. There are no financial covenants relating to the 2.625% Senior Notes, the 3.00% Senior Notes or the 4.950% Senior Notes; however, all are subject to cross-acceleration provisions. Credit Ratings The Company’s credit ratings, which were independently developed by the following credit agencies, are detailed below: •S&P Global Ratings reaffirmed the Company’s corporate credit rating of BBB (stable outlook) in September 2024. •Moody’s Investors Service affirmed the Company’s corporate credit rating of Baa2 (stable outlook) in August 2024. •Fitch Ratings reaffirmed the Company’s corporate credit rating of BBB+ (stable outlook) in February 2026. Off-Balance Sheet Arrangements The Company had $27.9 million of letters of credit as of June 30, 2026, primarily issued as security for insurance and other performance obligations. Of the $27.9 million of letters of credit, only $4.1 million reduced the Company’s borrowing capacity under the Revolving Facility as of June 30, 2026. Except as disclosed above, the Company has no off-balance sheet arrangements that currently have or are reasonably likely to have a material effect on the Company’s consolidated financial condition, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources. Critical Accounting Estimates There have been no changes to the Company’s critical accounting estimates described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. 34 Table of Contents Non-GAAP Disclosures The Company prepares its financial statements in accordance with U.S. GAAP. To supplement its U.S. GAAP financial results, the Company presents certain non-GAAP financial measures. Management uses these non-GAAP measures to evaluate operating performance, assess trends, allocate resources and support financial and operational decision-making. Management believes these measures provide investors with additional insight into the Company’s ongoing business performance and enhance comparability across reporting periods by excluding the impact of items that management does not consider reflective of ongoing operations. Management uses Adjusted EBITDA as its measure of segment performance. Management believes it is a useful indicator of the strength and performance of the Company and its segments’ ongoing business operations as well as a way for investors to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies. The Company defines its non-GAAP measures below and presents reconciliations of these non-GAAP measures to their most directly comparable U.S. GAAP measures in the tables that follow. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below. •Organic sales are calculated as Net sales excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation. •Adjusted gross profit is calculated as Gross profit, adjusted to exclude the impact of fair value inventory step-up charges and restructuring-related charges. •Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales. •Adjusted net income attributable to IDEX is calculated as Net income attributable to IDEX, adjusted to exclude the impact of Restructuring expenses and asset impairments and other restructuring-related charges, acquisition-related intangible asset amortization and legal settlements and contingencies, all net of the statutory tax expense or benefit. •Adjusted diluted EPS attributable to IDEX is calculated as Adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding. •Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, income taxes, depreciation and amortization, or consolidated EBITDA, adjusted to exclude the impact of Restructuring expenses and asset impairments and other restructuring-related charges and legal settlements and contingencies. •Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by Net sales. •Free cash flow is calculated as cash flows from operating activities less capital expenditures. This non-GAAP measure is discussed and reconciled to its most directly comparable U.S. GAAP measure in the section above titled “Free Cash Flow.” The non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures prepared in accordance with U.S. GAAP and the reconciliations from those results should be carefully evaluated. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely. 35 Table of Contents Table 1. Reconciliations of the Change in Net Sales to Change in Organic Sales HST FMT FSDP IDEX Three Months Ended June 30, 2026 Change in net sales 14 % 2 % (1 %) 6 % Less: Net impact from acquisitions/divestitures(1) 2 % — % — % 1 % Impact from foreign currency(2) — % 1 % — % — % Change in organic sales 12 % 1 % (1 %) 5 % Six Months Ended June 30, 2026 Change in net sales 15 % 3 % 1 % 8 % Less: Net impact from acquisitions/divestitures(1) 2 % — % — % 1 % Impact from foreign currency(2) 2 % 1 % 2 % 2 % Change in organic sales 11 % 2 % (1 %) 5 % (1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture. (2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Table 2. Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (in millions) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Gross profit $ 426.8 $ 392.2 $ 824.9 $ 761.1 Restructuring-related charges(1) 0.5 — 0.5 — Adjusted gross profit $ 427.3 $ 392.2 $ 825.4 $ 761.1 Net sales $ 920.6 $ 865.4 $ 1,807.5 $ 1,679.7 Gross margin 46.3 % 45.3 % 45.6 % 45.3 % Adjusted gross margin 46.4 % 45.3 % 45.7 % 45.3 % (1) Restructuring-related charges represent accelerated depreciation related to the anticipated closure of a facility in the HST segment. 36 Table of Contents Table 3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except for per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Reported net income attributable to IDEX $ 143.4 $ 131.6 $ 263.4 $ 227.1 Restructuring expenses and asset impairments and other restructuring-related charges(1) 3.3 0.4 10.7 17.9 Tax impact on restructuring expenses and asset impairments and other restructuring-related charges (0.8) (0.2) (2.5) (4.3) Legal settlements and contingencies(2) 0.9 — (2.8) — Tax impact on legal settlements and contingencies 0.3 — 1.1 — Acquisition-related intangible asset amortization 33.2 32.0 67.0 63.5 Tax impact on acquisition-related intangible asset amortization (7.9) (7.3) (15.9) (14.7) Adjusted net income attributable to IDEX $ 172.4 $ 156.5 $ 321.0 $ 289.5 Reported diluted EPS attributable to IDEX $ 1.93 $ 1.74 $ 3.54 $ 3.00 Restructuring expenses and asset impairments and other restructuring-related charges(1) 0.05 0.01 0.15 0.24 Tax impact on restructuring expenses and asset impairments and other restructuring-related charges (0.01) — (0.03) (0.06) Legal settlements and contingencies(2) 0.01 — (0.04) — Tax impact on legal settlements and contingencies — — 0.01 — Acquisition-related intangible asset amortization 0.45 0.42 0.90 0.83 Tax impact on acquisition-related intangible asset amortization (0.11) (0.10) (0.21) (0.19) Adjusted diluted EPS attributable to IDEX $ 2.32 $ 2.07 $ 4.32 $ 3.82 Diluted weighted average shares outstanding 74.2 75.5 74.3 75.7 (1) Restructuring expenses and asset impairments and other restructuring-related charges consist of the following: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Restructuring expenses and asset impairments $ 2.8 $ 0.7 $ 10.2 $ 18.2 Less: Restructuring expenses and asset impairments attributable to noncontrolling interest(a) — (0.3) — (0.3) Other restructuring-related charges(b) 0.5 — 0.5 — Restructuring expenses and asset impairments and other restructuring-related charges $ 3.3 $ 0.4 $ 10.7 $ 17.9 (a) Restructuring expenses and asset impairments recorded during the three and six months ended June 30, 2025, respectively, included charges of $0.6 million recognized by the Company’s joint venture, $0.3 million of which was attributable to noncontrolling interest. (b) Other restructuring-related charges represent accelerated depreciation related to the anticipated closure of a facility in the HST segment. (2) Legal settlements and contingencies represent settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the FMT segment and a class action lawsuit at Corporate, net of estimated settlement costs related to certain legal matters within the HST segment. 37 Table of Contents Table 4. Reconciliations of Net Income to Adjusted EBITDA (in millions) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Reported net income $ 143.4 $ 131.1 $ 263.3 $ 226.5 Provision for income taxes 42.7 38.8 79.8 67.9 Interest expense – net 15.1 15.6 31.1 31.7 Depreciation(1) 20.2 19.0 40.1 37.4 Amortization 33.2 32.0 67.0 63.5 Restructuring expenses and asset impairments 2.8 0.7 10.2 18.2 Legal settlements and contingencies(2) 0.9 — (2.8) — Adjusted EBITDA $ 258.3 $ 237.2 $ 488.7 $ 445.2 Adjusted EBITDA Components HST $ 119.3 $ 95.0 $ 225.3 $ 182.4 FMT 110.3 108.7 209.0 204.0 FSDP 54.9 56.4 110.7 110.6 Corporate and other (26.2) (22.9) (56.3) (51.8) Total Adjusted EBITDA $ 258.3 $ 237.2 $ 488.7 $ 445.2 Net sales $ 920.6 $ 865.4 $ 1,807.5 $ 1,679.7 Net income margin 15.6 % 15.1 % 14.6 % 13.5 % Adjusted EBITDA margin 28.1 % 27.4 % 27.0 % 26.5 % (1) Depreciation includes accelerated depreciation related to the anticipated closure of a facility in the HST segment, which was included in Restructuring-related charges in Table 2 and in Restructuring expenses and asset impairments and other restructuring-related charges in Table 3 above. (2) Legal settlements and contingencies represent settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the FMT segment and a class action lawsuit at Corporate, net of estimated settlement costs related to certain legal matters within the HST segment. 38 Table of Contents